We are thrilled to announce AICURA medical's participation in the upcoming Clinical Trials on Alzheimer's Disease (CTAD) conference which will be held in Madrid on October 29, 2024. Our Chief Technology Officer, Dr. Konstantin Thierbach, will present our latest research on the differential diagnosis of Alzheimer’s Disease (AD) and frontotemporal dementia (FTD) subtypes using an innovative multimodal AI system (TelDem). This research is being conducted in a value-based partnership with Prof. Matthias Schroeter from the Max Planck Institute for Human Cognitive and Brain Sciences (MPI CBS). Together, we are pushing the boundaries of AI-driven diagnostics in neurodegenerative diseases.
Our multi-modal AI system, leverages real-world clinical data, which is often incomplete and high-dimensional, to achieve:
- Superior Diagnostic Accuracy: over 10% improvement over single-modality classifiers.
- Multiclass Discrimination: effectively distinguishing between various dementia subtypes.
- Interpretability: providing insights into clinical biomarkers crucial for decision-making.
TelDem's powerful multimodal AI integrates Cognitive and Behavioral Assessments, T1-weighted MRI Scans, and Demographic Information, enabling more comprehensive and accurate diagnoses that enhance clinical workflows and advance research. TelDem's flexible architecture also adapts quickly to optimize clinical trials, stratify patients, and can support drug development at different stages.
We invite conference attendees to visit our poster (LP106, Themes 13: Digital health/E-trials) to learn more about TelDem and its potential impact on neurodegenerative disease research and treatments. Our team is looking forward to discussing collaboration opportunities and answering questions.
If you are not attending CTAD 2024, request an intro today to discover how AICURA can help optimize your clinical trials.
